期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

良性前列腺增生患者的药物治疗

下载PDF
导出
摘要 目的为了解联合服用5-α还原酶抑制剂和α1-受体阻滞剂在中老年良性前列腺增生(BPH)患者中的疗效。方法 60位BPH患者随机分成治疗组(30例)和对照组(30例),治疗组在接受一般治疗措施基础上,联合服用5-α还原酶抑制剂非那雄胺片和α1-受体阻滞剂多沙唑嗪控释片,而对照组仅接受一般治疗措施,3月后比较两组患者在国际前列腺症状评分、生活质量评定、最大尿流率和前列腺体积上的差异。结果与对照组相比,治疗组患者在改善自觉症状(P<0.01)、提高生活质量(P<0.01)、降低最大尿流率(P<0.05)方面,差异有统计学意义,而在缩小前列腺体积方面,差异没有统计学意义(P>0.05)。结论联合服用5-α还原酶抑制剂和α1-受体阻滞剂是中老年BPH患者的重要治疗手段。
作者 嵇艳兰
机构地区 浙江省德清县人民医院
出处 《海峡药学》 2011年第7期119-120,共2页 Strait Pharmaceutical Journal
关键词 良性前列腺增生 药物治疗
分类号 R969.4 [医药卫生—药理学]
  • 相关文献

参考文献6

  • 1Mary MC, Michael JB. Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia [J ] . Am J Med, 2005, 118:1331-1339.
  • 2American Urological Association Practice Guideliness Committee.American urological asociation guildeline on management of benign prostatic hyperplasia(2003). Diagnosis and treatment recommen- dations [J] .J Urol, 2003, 170 : 530-47.
  • 3叶章群.良性前列腺增生的诊断和治疗[J].中华老年医学杂志,2006,25(5):390-392. 被引量：46
  • 4魏强,李涛.良性前列腺增生的药物治疗[J].中华老年医学杂志,2006,25(7):557-559. 被引量：20
  • 5Kok ET, Bohnen AM, Jonkheijm R, et al. Simple case definition of clinical benign prostatic hyperplasia, based on international prostate symptom score, predicts general practitioner consultation rates [J]. Urology, 2006, 68:784-789.
  • 6Mcconnell JD, Roehrbom CG, Bautista OM, et al. The long-term effect of doxazosin, finastetide, and combination therapy on the clinical progression of benigh prostatic hype rplasia [J].N Engl J Med, 2003, 349 : 2387-2398.

二级参考文献12

  • 1McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med, 1998, 338 :557-563.
  • 2Kaplan SA. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5 alpha-reductase inhibitor dutasteride: results of 4-year studies. J Urol, 2006, 175:2211-2212.
  • 3Maria McCrohan A, Morrissey C, O' keane C et al.Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer, 2006, 106:2743-2752.
  • 4Lepor H,Williford WO,Barry MJ,et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med,1996, 335:533-539.
  • 5Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia : the Prospective European Doxazosin and Combination Therap (PREDICT) trial.Urology,2003,61 : 119-126.
  • 6McConnell JD, Roehrborn CG,Bautista OM ,et al. The long-term effect of eoxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 2003, 349:2387-2398.
  • 7Fitzpatrick JM, Desgrandchamps F. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. BJU International, 2005, 95:575-579.
  • 8Mary MC,Michael JB.Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Am J Med,2005,118:1331-1339.
  • 9American Urological Association Practice Guidelines Committee.American Urological Association guideline on management of benign prostatic hyperplasia (2003).Chapter 1.Diagnosis and treatment recommendations.J Urol,2003,170:530-547.
  • 10Roehrborn CG,Boyle P,Nichol JC,et al.Efficacy and safety of a dual inhibitor of 5-alpha reductase types 1 and 2(dutasteride) in men with benign prostatic hyperplasia.Urology,2002,60:434-441.

共引文献62

海峡药学
2011年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部